ReviewACS omega2025
Vanillin Derivatives in Drug Design: Structure-Activity Relationship (SAR) Hotspots and Synthetic Pathways for Enhanced Pharmacological Activity.
Review in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Design, synthesis, and biological evaluation of vanillin-piperidone hybrids with potent anticancer activity and a favourable genotoxic profile.RSC advances · 2026Article
- Synthesis, Antibacterial Evaluation, and Chemometric Profiling of a Vanilloid-Based Compounds Library Active AgainstAntibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug discovery often uses privileged molecular scaffolds, such as vanillin, which are naturally found in plants for drug design and synthesis. Incorporating vanillin into standard chemical structures and synthesizing novel derivatives with active scaffolds are vital for developing effective therapeutic candidates. The aromatic ring of vanillin contains functional groups such as aldehyde, hydroxyl, and ether, which facilitate its modification and the generation of various resultant derivatives with promising biological activities. Consequently, numerous strategies have been developed and incorporated into synthetic pathways to produce biologically potent vanillin derivatives. Vanillin-based compounds have demonstrated effectiveness against a wide range of emerging infectious diseases. This review focuses on the key structure-activity relationship hotspots within vanillin derivatives that influence their biological activity. By examining the synthetic pathways developed over the past decade (2014-2025), we highlight how targeted modifications at specific SAR hotspots can enhance the therapeutic potential of these compounds, such as antitubercular, antioxidant, antimalarial, anticancer, and anti-inflammatory properties.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.